荣昌生物股价跌5.21%，财通证券资管旗下1只基金重仓，持有13.73万股浮亏损失69.22万元

Core Viewpoint - Rongchang Biopharmaceuticals experienced a decline of 5.21% in stock price, reaching 91.70 CNY per share, with a total market capitalization of 51.683 billion CNY as of November 5 [1] Company Overview - Rongchang Biopharmaceuticals, established on July 4, 2008, and listed on March 31, 2022, is located in the Yantai Free Trade Zone, Shandong, China [1] - The company focuses on innovative biopharmaceuticals, particularly in the fields of antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies [1] - The main revenue sources are from product sales (99.46%), material sales (0.38%), and leasing services (0.16%) [1] Fund Holdings - According to data, one fund under Caitong Securities Asset Management holds a significant position in Rongchang Biopharmaceuticals, with 137,300 shares, accounting for 5.81% of the fund's net value [2] - The fund, Caitong Consumer Select Mixed A (005682), has a total scale of 244 million CNY and has reported a year-to-date return of 48.48% [2] Fund Manager Performance - The fund manager, Yu Yang, has been in position for 7 years and 113 days, with the fund's total assets amounting to 787 million CNY [3] - During Yu Yang's tenure, the best fund return was 170.41%, while the worst return was -48.65% [3]